Exposure–response of ciclosporin and methotrexate in children and young people with severe atopic dermatitis: a secondary analysis of the TREatment of severe Atopic dermatitis Trial (TREAT)
Authors:
Open Access
- 1 April 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (8) , 1623-1627
Abstract
This is a secondary analysis of a multicentre randomized controlled trial of ciclosporin and methotrexate in children and young people (CYP) with severe atopic dermatitis (AD). Longitudinal trough ciclosporin and erythrocyte methotrexate polyglutamate (MTX-PG) concentrations were measured to evaluate their associations with treatment response and adverse events. Both ciclosporin (4 mg kg–1 daily) and methotrexate (0.4 mg kg–1 weekly) led to a significant reduction in disease severity scores over the 36-week treatment period. Higher trough ciclosporin concentrations were associated with lower disease severity scores and may serve as a useful tool for therapeutic drug monitoring of ciclosporin in CYP with AD. However, in contrast to a previously published study, steady-state erythrocyte-MTX-PG concentrations showed no significant association with treatment response. Drug concentrations were comparable between patients with and without drug-related adverse events.Keywords
Funding Information
- UK Medical Research Council
- National Institute for Health Research
- Efficacy and Mechanism Evaluation (15/EE/0328)
This publication has 10 references indexed in Scilit:
- The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children: results from the TREAT trialBritish Journal of Dermatology, 2024
- Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trialBritish Journal of Dermatology, 2023
- A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitisBritish Journal of Clinical Pharmacology, 2022
- The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate‐to‐severe atopic eczema*British Journal of Dermatology, 2020
- Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic reviewPediatric Dermatology, 2019
- Trough (C0) and 2‐hour postdose (C2) cyclosporine monitoring in patients with moderate‐to‐severe psoriasisJournal of the European Academy of Dermatology and Venereology, 2019
- A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)British Journal of Dermatology, 2018
- Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT surveyJournal of the American Academy of Dermatology, 2017
- The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in childrenJournal of the American Academy of Dermatology, 2014
- The European treatment of severe atopic eczema in children taskforce (TREAT) surveyBritish Journal of Dermatology, 2013